Admission Date:  [**2120-10-25**]              Discharge Date:   [**2120-10-31**]  Date of Birth:  [**2055-7-14**]             Sex:   F  Service: MEDICINE  Allergies: No Known Allergies / Adverse Drug Reactions  Attending:[**First Name3 (LF) 3984**] Chief Complaint: Sepsis, respiratory distress  Major Surgical or Invasive Procedure: None  History of Present Illness: 65F w/ h/o metastatic breast cancer to breast and lungs currently receiving CMT (cycle 1, day 19), brought to the ED by rehab for abnormal labs.
She is usually incontinent of bowel and bladder, and denies diarrhea, abdominal pain, brbpr, melena, dysuria, or hematuria.
She denies cough, SOB, chest pain, headache, photophobia, neck stiffness.
ED course: T 100.6, EKG NSR at 83 w/ TWF, received vancomycin, cefepime and IVF.
She underwent 4 cycles of adriamycin and cyclophosphamide followed by radiation therapy, completed in [**2108**].
[**2119-1-20**]: Presented with ear complaints and nasal congestion, initially thought to be related to swimmer's ear.
She was given a course of antibiotics and nasal sprays with no resolution.
[**2119-2-10**] biopsy by FNA showed groups of atypical epithelial cells consistent with poorly-differentiated carcinoma.
On [**2119-2-13**], the left lung lesion was biopsied and showed adenocarcinoma with immunostaining positive for Cytokeratin 7 in the tumor cells, but negative for cytokeratin 20, CDX-2, TTF-1, Mammoglobin, GCDFP, ER and PR immunostains.
HER2 amplification was not found.
Her recent chemotherapy treatment history follows:  METASTATIC CANCER TREATMENT HX FIRST LINE THERAPY: [**2119-2-20**]: Started on trial 09-312; This is a Phase 3 Randomized Study of Gemcitabine and Carboplatin with or without BSI201 in patients with triple negative metastatic breast cancer.
[**Male First Name (un) **] was randomized to Arm B: Gemcitabine, Carboplatin, and BSI201; [**2119-3-10**] - Cycle 1 D1 Completed 9 cycles, stopped due to progression; Patient did have treatment delays and dose reductions due to thrombocytopenia-ENDED [**2119-10-20**] SECOND LINE THERAPY: Paclitaxel 80mg/m2 weekly, 3 week on/1 week off.
Stopped due to progression seen in by new liver and brain mets.
Now she also received radiation therapy.
Physical Exam: VS: 96.6, 100/70, 77, 18, 97% 2L Gen: thin F in NAD HEENT: right mandibular mass, atraumatic, sclera anicteeric Neck: supple CV: RRR, no edema Lungs: decreased BS at left mid-lower lung fields, no crackles/wheezes noted, no retractions, good effort Abd: +BS, soft, NTND, no mass/hsm, no rebound/guarding Ext: no c/c/e Neuro: A&O x 3  Pertinent Results: [**2120-10-25**] 03:10AM   LACTATE-1.7 [**2120-10-25**] 02:55AM   GLUCOSE-102* UREA N-20 CREAT-0.6 SODIUM-139 POTASSIUM-3.0* CHLORIDE-98 TOTAL CO2-34* ANION GAP-10 [**2120-10-25**] 02:55AM   CALCIUM-7.9* PHOSPHATE-2.6* MAGNESIUM-1.5* [**2120-10-25**] 02:55AM   WBC-0.2*# RBC-2.53* HGB-7.4* HCT-21.5*# MCV-85 MCH-29.1 MCHC-34.3 RDW-17.8* [**2120-10-25**] 02:55AM   NEUTS-16* BANDS-0 LYMPHS-68* MONOS-12* EOS-0 BASOS-0 ATYPS-0 METAS-0 MYELOS-0 NUC RBCS-9* OTHER-4* [**2120-10-25**] 02:55AM   HYPOCHROM-OCCASIONAL ANISOCYT-1+ POIKILOCY-NORMAL MACROCYT-NORMAL MICROCYT-1+ POLYCHROM-OCCASIONAL [**2120-10-25**] 02:55AM   PLT SMR-VERY LOW PLT COUNT-27*# [**2120-10-25**] 02:55AM   PT-14.7* PTT-22.0 INR(PT)-1.3*  CXR: left lower lobe opacity, enlarged from [**7-10**] (my read) CT head (prelim read): 1.
started empirically on vanc/cefepime and pancultured but no obvious source for infection was found, cultures were neg, and CXR negative initially.
On the evening of hospital day 3 pt began to desat to the 80s but improved with oxygen via nasal cannula.
The next morning, pt desatted again to the 80s and was less responsive to oxygen, but O2 sats improved after nebs and lasix.
She continued to desat after receiving nebs and was transferred to the [**Hospital Unit Name 153**].
She continued to retain CO2 and her respirations became more labored.
The possibility of intubation was again discussed with the patient and she reported that she did not want to be intubated.
The decision to change her care to comfort was made following discussions with her health care proxy.
She was continued on seizure prophylaxis and valproic acid.
Thought to be multifactorial, [**2-21**] possible seizures, deconditioning, and orthostasis/autonomic dysfunction.
She was continued on fludrocortisone and seizure prophylaxis and this was not an active issue.
Medications on Admission: Cyclophosphamide Dexamethasone 6g mg po bid Fludrocortisone 0.1 mg po daily Keppra 500 mg po TID Omeprazole 20 mg po daily Trazodone 50 mg po qhs Valproic acid 500 mg po TID Calcium Ibuprofen prn Pyridoxine prn Sodium chloride 1 g TID Vitamin E  Discharge Medications: Expired  Discharge Disposition: Expired  Discharge Diagnosis: Hypercapneic hypoxemic respiratory failure Breast Cancer  Discharge Condition: Expired  Discharge Instructions: Expired  Followup Instructions: Expired                               [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) 2437**] MD [**MD Number(1) 2438**]
